Established small‐molecule tyrosine kinase inhibitors (TKIs) target epidermal growth factor receptor (EGFR) and are effective in non‐small cell lung cancer (NSCLC) patients with activating and sensitizing EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.